# A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.

> **NCT00077974** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 106 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** SU011248

## Key facts

- **NCT ID:** NCT00077974
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2010-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077974, "A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00077974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*